<DOC>
	<DOCNO>NCT02718495</DOCNO>
	<brief_summary>This trial consist two part : first part enroll subject cystic fibrosis ( CF ) mutation single ascend dose ( SAD ) treatment group . The second part enroll adult subject CF mutation multiple ascend dose ( MAD ) treatment group . At least 36 subject enrol . The SAD treatment group comprise least 3 cohort subject randomize either PTI-428 placebo house close clinical site check Day -1 stay Day 4 . Subjects return clinical site Day 7 final follow-up visit . The Safety Review Committee ( SRC ) convene completion cohort evaluate safety relevant data . The decision whether escalate dose make complete cohort . Following conclusion least 3 SAD treatment group sufficient review study data approval SRC , second set adult subject diagnose cystic fibrosis participate assign MAD treatment group . The MAD treatment group comprise least 3 cohort subject randomize either PTI-428 placebo house close clinical site check Day -1 stay Day 4 . Subjects return clinical site daily Days 5-10 Day 12 outpatient follow visit . Subjects return clinic Day 14 final follow-up visit . Each dose administer daily ( QD ) total 7 Days . The SRC convene completion cohort evaluate safety relevant data . The decision whether escalate dose make complete cohort .</brief_summary>
	<brief_title>Study Assessing PTI-428 Safety , Tolerability , Pharmacokinetics Subjects With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis CF . Forced expiratory volume 1 second ( FEV1 ) &gt; 50 % predict prebronchodilator . Nonsmoker nontobacco user minimum 30 day prior screen duration study . Participation another clinical trial treatment investigational agent within 30 day 5 halflives , whichever longer , prior Study Day 1 . History cancer within past five year ( exclude nonmelanoma skin cancer ) . History organ transplantation . History alcohol drug abuse dependence within 12 month screen determined Investigator . Male female childbearing potential , unless use highly effective method contraception participation clinical study 4 week termination study . Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>